FDA Issues Complete Response Letter Regarding New Drug Application for Iluvien
Links shared publicly online about this topic.
- 595total visits
FDA Issues Complete Response Letter Regarding New Drug Application for Iluvien
View full resource at drugs.com
Tags: Edema, Diabetes, Drug, Clinical Trial, FDA, News
Most Recently Shared on January 9, 2011 at 12:10 am By:
FDA Issues Complete Response Letter Regarding New Drug Application for Iluvien: WATERTOWN, Mass.--(BUSINES... http://bit.ly/eiHec9 #drug
FDA Issues Complete Response Letter to NDA for Adasuve - MPR
empr.com — “Alexza Pharmaceuticals announced that it has received a complete response letter from the FDA regarding its New Drug Application (NDA) for Adasuve (Staccato loxapine) inhalation powder, 5mg and 10mg, for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.” View full resource at empr.com
Most Recently Shared on May 7, 2012 at 3:35 pm By:
FDA Issues Complete Response Letter to NDA for #Adasuve #Alexza #loxapine #inhalation #agitation http://t.co/UloQRAV8
FDA Issues Complete Response Letter to NDA for Alogliptin/Pioglitazone - MPR
empr.com — “Takeda announced that it received a complete response letter from the FDA regarding its New Drug Applications (NDAs) for alogliptin and fixed-dose combination alogliptin and pioglitazone for the treatment of type 2 diabetes.” View full resource at empr.com
Most Recently Shared on April 26, 2012 at 5:01 pm By:
FDA Issues Complete Response Letter to NDA for Alogliptin/Pioglitazone #diabetes #takeda http://t.co/KNCMpJxG
FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter
marketwire.com — “CONSHOHOCKEN, PA--(Marketwire - Aug 30, 2011) - NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food @ Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (NP101 or Zelrix). A CRL is issued by the FDA's...” View full resource at marketwire.com
Most Recently Shared on August 30, 2011 at 12:43 pm By:
FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter: CONSHOHOCKE... http://t.co/rhjDXXz
Eisai receives FDA Complete Response Letter for Aricept Patch NDA
news-medical.net — “Eisai announced today that the United States Food and Drug Administration issued a Complete Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application of the Aricept® Patch.” View full resource at news-medical.net
Most Recently Shared on April 25, 2011 at 8:38 am By:
Eisai receives FDA Complete Response Letter for Aricept Patch NDA: Eisai announced today that the United States ... http://bit.ly/hQfu82
FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules
news-medical.net — “Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-” View full resource at news-medical.net
Most Recently Shared on February 2, 2011 at 9:10 am By:
News-Medical.Net Health News and Oncology
Oncology News: FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release c... http://bit.ly/hrM4wt
FDA denies approval of weight-loss drug
endocrinetoday.com — “The FDA has issued a complete response letter regarding the new drug application for combination naltrexone plus bupropion extended-release tabl” View full resource at endocrinetoday.com
Most Recently Shared on February 1, 2011 at 2:07 pm By:
#FDA denies approval of #weight-loss drug http://bit.ly/eDgrg4
Alimera receives FDA CRL for ILUVIEN NDA
news-medical.net — “pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that” View full resource at news-medical.net
Most Recently Shared on December 24, 2010 at 8:27 am By:
Alimera receives FDA CRL for ILUVIEN NDA: pSivida Corp., a leader in developing sustained release, drug delivery... http://bit.ly/hnuJBP
PharmaLive: FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta
pharmalive.com — “PharmaLive: FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta” View full resource at pharmalive.com
Most Recently Shared on November 1, 2010 at 6:12 pm By:
PharmaLive Pharma and Health News
Daily Advantage - FDA Rejects Biodel's Linjeta NDA - http://tinyurl.com/297errf
FDA Issues Complete Response Letter To VIVUS Regarding New Drug Application For QNEXA®
medicalnewstoday.com — “VIVUS, Inc. (Nasdaq: VVUS) announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigati” View full resource at medicalnewstoday.com
Most Recently Shared on October 30, 2010 at 1:05 pm By:
MNT Weight Loss News Health News
FDA Issues Complete Response Letter To VIVUS Regarding New Drug Application For QNEXA® http://mnt.to/3LTJ #weightloss
VIVUS receives FDA CRL for QNEXA NDA
news-medical.net — “VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.” View full resource at news-medical.net
Most Recently Shared on October 29, 2010 at 9:43 am By:
Obesity News: VIVUS receives FDA CRL for QNEXA NDA: VIVUS, Inc. announced today that it received a Complete Resp... http://twurl.nl/2kuu0v
FDA issues complete response letter to NDA for lorcaserin - MPR
empr.com — “Arena and Eisai announced that they received a complete response letter (CRL) from the FDA regarding the New Drug Application (NDA) for lorcaserin for weight management.” View full resource at empr.com
Most Recently Shared on October 25, 2010 at 4:49 pm By:
MPR News: FDA issues complete response letter to NDA for lorcaserin: Arena and Eisai announced that they received ... http://bit.ly/9E2GG1
FDA issues complete response letter to NDA for lorcaserin - ONA
oncologynurseadvisor.com — “Arena and Eisai announced that they received a complete response letter (CRL) from the FDA regarding the New Drug Application (NDA) for lorcaserin for weight management.” View full resource at oncologynurseadvisor.com
Most Recently Shared on October 25, 2010 at 4:07 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
FDA issues complete response letter to NDA for lorcaserin http://goo.gl/fb/a145n
Arena's NDA receives Complete Response Letter for lorcaserin
news-medical.net — “Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese” View full resource at news-medical.net
Most Recently Shared on October 25, 2010 at 5:25 am By:
News-Medical.Net Health News and Oncology
Oncology News: Arena's NDA receives Complete Response Letter for lorcaserin: Arena Pharmaceuticals, Inc. and Eisai... http://bit.ly/cNlODR
FDA issues complete response letter for BYDUREON NDA
news-medical.net — “Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON" (exenatide extended-release for injectable suspension).” View full resource at news-medical.net
Most Recently Shared on October 21, 2010 at 9:21 am By:
Obesity News: FDA issues complete response letter for BYDUREON NDA: Amylin Pharmaceuticals, Inc., Eli Lilly and ... http://twurl.nl/m7lzdz
Advertisement
